menu
    • menu
    [{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed ","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"VAL301","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"ValiRx \/ Undisclosed ","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ Undisclosed "},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Monash University"},{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Mitochondrial therapy","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"LUCA Science \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ University of Oxford"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"OvaStem","moa":"T Cell","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"BCI Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CSF1R kinase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"BCI Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"BCI Pharma \/ Mithra","highestDevelopmentStatusID":"4","companyTruncated":"BCI Pharma \/ Mithra"},{"orgOrder":0,"company":"Celmatix","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Evotec"},{"orgOrder":0,"company":"Celmatix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Not Applicable"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Fast Track Initiative","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"Mitochondrial-based Therapy","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"LUCA Science \/ Fast Track Initiative","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ Fast Track Initiative"},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Mushroom-Derived Biopolymer","moa":"Cervical mucus","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Organon","amount2":0.37,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Organon \/ Cirqle Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Organon \/ Cirqle Biomedical"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Rejoy Corporation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JW-500","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Safety Shot \/ Rejoy Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Safety Shot \/ Rejoy Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"MedinCell","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Progesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"MedinCell","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AMY109","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"NEXT Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vasalgel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"NEXT Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NEXT Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NEXT Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Celmatix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"BCI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Mithra Pharmaceuticals \/ BCI Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Mithra Pharmaceuticals \/ BCI Pharma"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institute of Child Health and Human Development","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ National Institute of Child Health and Human Development","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Bioscience \/ National Institute of Child Health and Human Development"},{"orgOrder":0,"company":"Celmatix","sponsor":"Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Ache Laboratorios Farmaceuticos SA","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Ache Laboratorios Farmaceuticos SA"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Bio-identical Progesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Bioscience \/ National Institutes of Health"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vectura Ltd

                            United Kingdom
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxytocin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Monash University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Vectura Partners with Monash University to Support Development of Inhaled Oxytocin to Prevent Postpartum Haemo...

                            Details : Vectura will support the development of a single use device/formulation combination for evaluation in Phase I of inhaled oxytocin, and then expedite technical transfer to a commercial manufacturer to advance to Phase III and commercial launch.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 14, 2020

                            Lead Product(s) : Oxytocin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Monash University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Skyepharma Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Daré Bioscience

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $49.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Daré Bioscience Receives Grant Funding to Support Novel Contraceptive Technology

                            Details : Proceeds will support nonclinical development of DARE-LARC1, a drug delivery platform designed for precise, long-term levonorgestrel delivery over months or years through a single device.

                            Brand Name : DARE-LARC1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 23, 2024

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $49.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Daré Bioscience

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Daré Bioscience Achieves Proof-of-Concept for DARE-LARC1 Device for Women’s Health

                            Details : DARE-LARC1 is an investigational, drug delivery platform designed to store and precisely deliver levonorgestrel therapeutic doses over months or years through a single device.

                            Brand Name : DARE-LARC1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2024

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Daré Bioscience

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bio-identical Progesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Sh...

                            Details : The funding will support the clinical development of Daré’s novel, investigational intravaginal ring (IVR), DARE-PTB1 (progesterone), being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment opt...

                            Brand Name : DARE-PTB1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : Bio-identical Progesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celmatix

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Celmatix

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Ache Laboratorios Farmaceuticos SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Celmatix and Aché Laboratórios Announce Collaboration to Investigate a Novel Melatonin Receptor Agonists for...

                            Details : The collaboration aims to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Ache, for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS).

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 08, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Ache Laboratorios Farmaceuticos SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Daré Bioscience

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : National Institute of Child Health and Human Development

                            Deal Size : $0.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for th...

                            Details : The funding will be used for supporting development of potential new therapeutic intervention for the treatment and prevention of idiopathic preterm birth.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 31, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : National Institute of Child Health and Human Development

                            Deal Size : $0.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mithra Pharmaceuticals

                            Belgium arrow
                            BMWS24
                            Not Confirmed

                            Mithra Pharmaceuticals

                            Belgium arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : BCI Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program

                            Details : Colony-stimulating factor 1 receptor (CSF-1R) is a cell-surface tyrosine kinase receptor and a key regulator of macrophage biology and homeostasis andpromising therapeutic strategy for cancer treatment.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 15, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : BCI Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Celmatix

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Celmatix

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celmatix Launches Novel PCOS Drug Program

                            Details : Celmatix launches novel pcos program with the potential to expand into the treatment of endometriosis and menopausal symptoms. It is aimed at restoring ovarian function in a way that addresses the root cause of all the symptoms.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            April 13, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            NEXT Life Sciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            NEXT Life Sciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vasalgel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NEXT Life Sciences Announces Launch of Plan A™ Birth Control for Men

                            Details : Plan A™ (vasalgel) a hydrogel technology, which is in preclinical stage of developement, it is designed to give men birth control that is long-lasting, non-hormonal, and reversible on-demand.

                            Brand Name : Plan A

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 22, 2023

                            Lead Product(s) : Vasalgel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Chugai Pharmaceutical

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Chugai Pharmaceutical

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMY109

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chugai’s Anti-IL-8 Recycling Antibody AMY109, Improves Inflammation and Fibrosis in Endometriosis in an Indu...

                            Details : AMY109 is a novel therapeutic antibody with a recycling function that binds to IL-8 (an inflammatory cytokine) and improves inflammation and fibrosis in endometriosis.

                            Brand Name : AMY109

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 24, 2023

                            Lead Product(s) : AMY109

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth